Clinical Trials Logo

Thyroid Neoplasms clinical trials

View clinical trials related to Thyroid Neoplasms.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT04204928 Approved for marketing - Clinical trials for Non-Small Cell Lung Cancer

Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC

Start date: n/a
Phase:
Study type: Expanded Access

This is a global, multicenter, open-label pre-approval access program to provide access to pralsetinib (BLU-667) until such time that pralsetinib becomes available through other mechanisms or the Sponsor chooses to discontinue the program.

NCT ID: NCT03533361 Approved for marketing - Thyroid Cancer Clinical Trials

Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil

Start date: n/a
Phase:
Study type: Expanded Access

This is an Expanded Access Program to make lenvatinib available to participants with radioiodine-refractory differentiated thyroid cancer in Brazil. Participants who have no other treatment options available, and who, in the opinion and clinical judgment of the treating physician, would benefit from treatment with lenvatinib will be enrolled. This is a multicenter, open-label program consisting of 2 phases: a 28-day pretreatment phase (including screening) and a treatment phase. Treatment will be provided as long as there is a clinical benefit based on tumor assessments performed according to the center's standard of care and the judgment of the participant's treating physician.

NCT ID: NCT02211222 Approved for marketing - Clinical trials for Differentiated Thyroid Cancer

An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

Start date: n/a
Phase: N/A
Study type: Expanded Access

This Expanded Access Program (EAP) consists of a Prerandomization Phase and a Randomization Phase. Only subjects with radioiodine-refractory DTC who fulfill the eligibility criteria will be treated. These subjects will be treated until progression of disease or unacceptable toxicity.

NCT ID: NCT01683110 Approved for marketing - Clinical trials for Medullary Thyroid Cancer

Expanded Access of Cabozantinib in Medullary Thyroid Cancer

Start date: n/a
Phase: N/A
Study type: Expanded Access

The objective of this study is to provide access to cabozantinib for eligible subjects with medullary thyroid cancer (MTC) pending approval of Exelixis' New Drug Application (NDA) by the FDA and commercial availability of cabozantinib.